

Josep DarbÀ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8316183/publications.pdf>

Version: 2024-02-01

61
papers

487
citations

759190

12
h-index

839512

18
g-index

80
all docs

80
docs citations

80
times ranked

778
citing authors

#	ARTICLE	IF	CITATIONS
1	Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 481-488.	1.4	2
2	Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , .	1.4	0
3	Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-5.	1.4	0
4	Hospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis. Journal of Medical Economics, 2022, 25, 381-385.	2.1	2
5	Hospital Incidence and Medical Costs of Female Breast Cancer in Spain: A Retrospective Multicenter Study. Current Cancer Therapy Reviews, 2022, 18, 285-291.	0.3	1
6	Ambulatory and hospital care of glaucoma in Spain and associated medical costs. Journal of Medical Economics, 2022, 25, 769-773.	2.1	0
7	Disease burden on health care by pain severity and usual analgesic treatment in patients with symptomatic osteoarthritis: a Spanish nationwide health survey. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 711-719.	1.4	6
8	Atopic dermatitis in specialized centers in Spain: a retrospective analysis of incidence and costs (2000-2017). Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 737-742.	1.4	0
9	Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 87-92.	1.4	7
10	Economic impact of dry eye disease in Spain: A multicentre retrospective insurance claims database analysis. European Journal of Ophthalmology, 2021, 31, 328-333.	1.3	6
11	Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018). Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 425-431.	1.4	2
12	Removal Statement. Current Medical Research and Opinion, 2021, 37, i-i.	1.9	0
13	Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110105.	2.7	4
14	Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-9.	1.4	0
15	Incidence, mortality and medical costs of patients hospitalized with melanoma in Spain: a retrospective multicentre observational study. Current Medical Research and Opinion, 2021, 37, 795-800.	1.9	0
16	Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. CKJ: Clinical Kidney Journal, 2021, 14, 2391-2400.	2.9	7
17	Economic Evaluation of the Use of FeNO for the Diagnosis and Management of Asthma Patients in Primary Care in Sweden. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 289-297.	1.9	3
18	Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in Spain (2008-2017): a retrospective multicentre study. Current Medical Research and Opinion, 2021, 37, 523-530.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Chronic inflammatory demyelinating polyneuropathy in Spain: a retrospective analysis of hospital incidence and medical costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-6.	1.4	2
20	Hospital incidence, mortality and costs of Alzheimer's disease in Spain: a retrospective multicenter study. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-6.	1.4	3
21	Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis. Journal of Medical Economics, 2020, 23, 1435-1440.	2.1	3
22	Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011-2017). Journal of Medical Economics, 2020, 23, 1623-1629.	2.1	9
23	Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis. Journal of Medical Economics, 2020, 23, 1477-1484.	2.1	6
24	Analysis of the management and costs of headache disorders in Spain during the period 2011-2016: a retrospective multicentre observational study. BMJ Open, 2020, 10, e034926.	1.9	5
25	Current status of lung cancer in Spain: a retrospective analysis of patient characteristics, use of healthcare resources and in-hospital mortality. Current Medical Research and Opinion, 2020, 36, 1201-1207.	1.9	1
26	Epidemiology and management of parathyroid gland disorders in Spain over 15 years: A retrospective multicentre analysis. PLoS ONE, 2020, 15, e0230130.	2.5	13
27	Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis. Clinical Drug Investigation, 2020, 40, 335-341.	2.2	7
28	Characteristics, management and medical costs of patients with depressive disorders admitted in primary and specialised care centres in Spain between 2011 and 2016. PLoS ONE, 2020, 15, e0228749.	2.5	1
29	Results after 10 years of colorectal cancer screenings in Spain: Hospital incidence and in-hospital mortality (2011-2016). PLoS ONE, 2020, 15, e0228795.	2.5	5
30	Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis. Orphanet Journal of Rare Diseases, 2020, 15, 8.	2.7	6
31	Epidemiology, management and costs of sepsis in Spain (2008-2017): a retrospective multicentre study. Current Medical Research and Opinion, 2020, 36, 1089-1095.	1.9	6
32	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine (United States), 2020, 99, e23506.	1.0	10
33	Current Status and Use of Resources of Lysosomal Storage Diseases: Analysis of a Spanish Claims Database. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 263-270.	1.2	2
34	Evaluation of productivity losses due to premature mortality from colorectal cancer. PLoS ONE, 2020, 15, e0244375.	2.5	5
35	Characteristics, comorbidities, and use of healthcare resources of patients with phenylketonuria: a population-based study. Journal of Medical Economics, 2019, 22, 1025-1029.	2.1	2
36	Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis. PLoS ONE, 2019, 14, e0223772.	2.5	5

#	ARTICLE	IF	CITATIONS
37	The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period. BMC Cancer, 2019, 19, 992.	2.6	16
38	The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 743-748.	1.4	10
39	Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis. Clinical Drug Investigation, 2019, 39, 379-384.	2.2	5
40	Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain. Health Policy and Technology, 2019, 8, 14-23.	2.5	1
41	Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. BMJ Open, 2019, 9, e031271.	1.9	5
42	Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources. BMC Cancer, 2019, 19, 1226.	2.6	28
43	Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 45-57.	1.4	1
44	Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain. Clinical Drug Investigation, 2018, 38, 801-811.	2.2	5
45	Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus “ from the Spanish National Health System perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 587-595.	1.4	17
46	Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 127-137.	1.9	5
47	A budget impact analysis of Spiromax® and Turbuhaler® for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 435-444.	1.9	4
48	Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance. Patient Preference and Adherence, 2016, 10, 135.	1.8	14
49	The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. International Journal of COPD, 2015, 10, 2335.	2.3	44
50	Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. ClinicoEconomics and Outcomes Research, 2015, 7, 105.	1.9	17
51	Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study. ClinicoEconomics and Outcomes Research, 2015, 7, 163.	1.9	8
52	Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain. ClinicoEconomics and Outcomes Research, 2015, 7, 387.	1.9	19
53	Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study. BMC Public Health, 2015, 15, 324.	2.9	32
54	Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine, 2014, 32, 5006-5012.	3.8	16

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. <i>Journal of Medical Economics</i> , 2014, 17, 215-222.	2.1	14
56	Pharmacoeconomic Outcomes for Pregabalin: A Systematic Review in Neuropathic Pain, Generalized Anxiety Disorder, and Epilepsy from a Spanish Perspective. <i>Advances in Therapy</i> , 2014, 31, 1-29.	2.9	12
57	A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 17-26.	0.6	7
58	Direct Medical Costs of Liquid Intravenous Immunoglobulins in Children, Adolescents, and Adults in Spain. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 566-575.	2.0	9
59	Eficacia de los antipsicóticos de segunda generación en el tratamiento de los síntomas negativos de esquizofrenia: un metaanálisis de ensayos clínicos aleatorizados. <i>Revista De Psiquiatría Y Salud Mental</i> , 2011, 4, 126-143.	1.8	12
60	Epidemiology and societal costs of gastroesophageal reflux disease and Barrett's syndrome in Germany, Italy and Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 225-232.	1.4	10
61	Parallel Imports of Pharmaceuticals in the European Union. <i>Pharmacoeconomics</i> , 1998, 14, 129-136.	3.3	19